Back to today’s briefing

Story perspectives

Moderna Stock Plummets 20% Amid Vaccine Demand Decline

1/13/2025

50 8

Summary

Story summary

Moderna's stock fell 20% after lowering its 2025 sales forecast to $1.5-$2.5 billion.
This decline stems from reduced demand for COVID-19 and RSV vaccines and rising competition.
The company intends to reduce costs by $1 billion in 2025 and $500 million in 2026.
Moderna seeks to diversify its product offerings to navigate post-pandemic market challenges.
Stock volatility highlights concerns over the long-term viability of vaccine revenue streams.

1 of 1

Story summary

Moderna's stock fell 20% after lowering its 2025 sales forecast to $1.5-$2.5 billion.
This decline stems from reduced demand for COVID-19 and RSV vaccines and rising competition.
The company intends to reduce costs by $1 billion in 2025 and $500 million in 2026.
Moderna seeks to diversify its product offerings to navigate post-pandemic market challenges.
Stock volatility highlights concerns over the long-term viability of vaccine revenue streams.